IKAR Email Format
Pharmaceutical Manufacturing501-1000 Employees
Ikaria, Inc. is a critical care company focused on developing and commercializing innovative therapies (drugs and devices) designed to address the significant needs of critically ill patients. The company’s lead product is INOMAX® (nitric oxide) for inhalation, the only FDA-approved drug for the treatment of hypoxic respiratory failure associated with pulmonary hypertension in term and near-term infants. It is offered through the INOMAX therapy package, an all-inclusive offering of drug product, drug-delivery system, on-site training and 24/7/365 technical assistance and support. The INOMAX therapy package is marketed in the USA, Puerto Rico, Canada, Australia, Mexico and Japan